Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Araris Biotech

Request full access

Building tomorrow's antibody-drug conjugates (ADCs)

Wädenswil, SwitzerlandFounded 2019Biotech & Life Sciences

About Araris Biotech

Araris Biotech AG is a biotechnology startup that specializes in the development of a unique antibody-drug conjugate (ADC) linker technology. This technology is used to create therapies that can selectively deliver potent drugs, often for cancer treatment, to diseased tissues while sparing healthy parts of the body. The company's technology addresses common issues with current ADC technologies, such as poor stability, high heterogeneity, limited solubility, and expensive and time-consuming development processes.

The company's proprietary linker platform allows for the attachment of drug payloads to readily available antibodies in a single step, without the need to modify or reduce the antibodies. This results in ADC therapies that are highly uniform, stable, and potent. The company's technology also allows for the creation of ADCs that are highly soluble, reducing the risk of clumping in water-based solutions like blood, which can reduce the efficacy of the therapy.

Araris Biotech's business model is based on the development and commercialization of its proprietary ADC linker technology. The company's primary clients are likely to be pharmaceutical and biotechnology companies that are developing ADC therapies. The company operates in the biotechnology and pharmaceutical markets, which are characterized by high levels of research and development activity and significant potential for growth.

In terms of revenue generation, Araris Biotech likely makes money by licensing its technology to other companies, potentially receiving upfront payments, milestone payments, and royalties on sales of products that incorporate its technology. The company may also generate revenue by collaborating with other companies to develop new ADC therapies.

Source: Dealroom company data

Araris Biotech in the Wädenswil ecosystem

Live from Dealroom

The Araris Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed7 investors entered at this stage

Series A4 investors entered at this stage

  • The Institute for Follicular Lymphoma Innovation
  • Wille Finance
  • Schroders Capital
  • Samsung Ventures

Series B and later3 investors entered at this stage

  • Paul Scherrer Institut
  • Grow Cluster Wädenswil
  • ETH Zurich
Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$1M

9 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Araris Biotech on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.